Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Oct
16
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Sep
29
New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress
Aug
30
UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older
Aug
07
New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
Apr
28
UCB Announces PDUFA Date for Bimekizumab
Apr
23
"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis
Apr
23
UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021
Feb
23
UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development